Gene Therapy for Batten Disease

This trial tests a gene therapy (scAAV9.CB.CLN6) to determine its potential benefits for children with CLN6 Batten disease, a rare genetic disorder causing severe brain and nervous system issues. Researchers aim to assess the therapy's safety and its ability to slow the disease or improve symptoms. Participants will receive the treatment via injection into the fluid around their spinal cord and undergo regular check-ups over five years. Children diagnosed with CLN6 and no other genetic brain disorders may be suitable candidates. As a Phase 1, Phase 2 trial, this research focuses on understanding the treatment's effects in people and measuring its effectiveness in an initial, smaller group.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that the gene therapy scAAV9.CB.CLN6 is generally safe for patients with CLN6 Batten disease. In a study with 12 patients, most side effects were mild and unrelated to the treatment. Patients were monitored for 6 to 39 months, which indicated that the therapy does not cause serious problems over time. Another study found that the therapy improved symptoms such as balance and movement in a similar condition. This offers hope that the therapy might be safe and effective for individuals with CLN6 Batten disease.¹²³⁴⁵

Researchers are excited about scAAV9.CB.CLN6 for Batten Disease because it represents a novel gene therapy approach. Unlike current treatments, which mainly focus on managing symptoms, scAAV9.CB.CLN6 aims to address the root cause by delivering a functional copy of the CLN6 gene directly to the brain cells affected by the disease. This targeted delivery method uses a specially engineered virus (scAAV9) to cross the blood-brain barrier, potentially offering a more effective and lasting impact on the progression of Batten Disease.

Research has shown that the scAAV9.CB.CLN6 gene therapy, which participants in this trial will receive, could help treat CLN6 Batten disease. In studies with mice, adding a functional human CLN6 gene corrected brain and behavior issues. Early results from human trials demonstrated improvements in movement and language skills in children with the disease. The therapy also helped prevent common signs of the disease in key brain areas related to vision. These early findings suggest that the gene therapy might slow the disease's progression and improve symptoms in affected children.¹²³⁴⁶